PER-035-02已完成未知
A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female
- •Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer. Patients must meet any subcriteria as detailed in the protocol.
- •Age greater than or equal to 18 years old
- •ECOG performance status of 0 to 1
- •Prior diagnosis of brain metastases from NSCLC eligible provided that the brain metastases have been adequately treated, patient is neurologically stable and no new or progressive brain metastases identified.
- •Meets protocol requirements for specified laboratory values
- •Written informed consent
- •Appropriate use of effective contraception if of childbearing potential
- •Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided they have been treated with no evidence of disease
排除标准
- •Prior chemotherapy for any stage of NSCLC
- •Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from prior procedures or therapy
- •Concurrent treatment or treatment within the last 2 years for any other malignancy
- •Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic medication)
- •Medical conditions that would interfere with taking oral medications
- •Patients with bone metastases as the only site of disease
- •Pregnant or nursing women
- •Known HIV positivity or AIDS-related illness
- •Patients with significant QTc prolongation at baseline
研究者
相似试验
进行中（未招募）
3 期
A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal Cancer (LEAP-017)unresectable non MSIH/dMMR mCRCJPRN-jRCT2031200453Shimoyama Ryo60
进行中（未招募）
1 期
A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal CancerColorectal CarcinomaMedDRA version: 20.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004289-20-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.434
进行中（未招募）
1 期
A Phase 3 Study of Lenvatinib Plus Pembrolizumab in Previously Treated Participants with Metastatic Colorectal CancerColorectal CarcinomaMedDRA version: 20.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864EUCTR2020-004289-20-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.434
进行中（未招募）
1 期
A pivotal randomized study of Lonafarnib (SCH 66336) versus placebo in the treatment of subjects with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who are platelet transfusion dependent with or without anemia.EUCTR2004-004685-32-ITSCHERING-PLOUGH200
进行中（未招募）
1 期
A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia - A pivotal study in CMML/MDSPlatelet Transfusion Dependence in Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) according to FAB criteriaEUCTR2004-004685-32-GRSchering-Plough Research Institute200